NanoViricides, Inc. (NNVC)

NanoViricides commissions animal study of broad-spectrum antiviral for measles

NanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral candidate NV-387. The company has commissioned a study using specially modified mice that express the human SLAM/CD150 protein, a key receptor the measles virus uses to infect cells.

NanoViricides president backs FDA's targeted COVID booster policy shift

NanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19 vaccine booster recommendations, calling it a “rational and scientific” shift that could help restore public trust in health institutions. The updated FDA guidance recommends COVID booster shots only for adults aged 65 and older, and for individuals aged six months and above with underlying conditions that put them at risk of severe disease.

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.

NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox

NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company's broader strategy to address a growing range of viral public health threats with no currently approved treatments. The Connecticut-based biotech firm recently received clearance from the Democratic Republic of Congo's National Ethics Committee to proceed with the submission following a review of Phase I safety data and promising results from preclinical Mpox studies in lethal animal models.

NanoViricides progresses antiviral portfolio as measles and MPox threats rise

NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid rising concern over vaccine failure and the lack of effective treatments. The Shelton, Connecticut-based company said it has initiated animal efficacy studies to evaluate NV-387 as a treatment for measles, noting there are currently no approved antiviral drugs for the disease.

NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC

NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug NV-387 for treating Mpox, a step toward regulatory submission in a region where the disease continues to spread. The approval, granted by the National Ethics Committee for Health (CNES) under the DRC's Ministry of Public Health, clears the company to submit a full clinical trial application (CTA) for NV-387, NanoViricides said.

NanoViricides advances measles drug development amid rising US cases

NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. The Shelton, Connecticut-based biotechnology firm said it has completed propagation of the measles virus in its biosafety level-2 virology lab and is preparing to conduct an animal model study to test its clinical-stage antiviral candidate NV-387.

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith.

NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative

The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.

Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold

NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials

NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.

NanoViricides announces readiness to combat bird flu with antiviral drug NV-387

NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.